Deep Brain Stimulation News and Research

RSS

Deep brain stimulation (DBS) is a surgical procedure used to treat a variety of disabling neurological symptoms—most commonly the debilitating symptoms of Parkinson’s disease (PD), such as tremor, rigidity, stiffness, slowed movement, and walking problems. The procedure is also used to treat essential tremor, a common neurological movement disorder. At present, the procedure is used only for patients whose symptoms cannot be adequately controlled with medications.

NewYork-Presbyterian/WCMC join new MDS Clinical Research Consortium

NewYork-Presbyterian/Weill Cornell Medical Center is one of six institutions selected to join the newly-founded MDS Clinical Research Consortium.

20 Jun 2012

Researchers unlock structure of STING protein

Researchers at Weill Cornell Medical College have unlocked the structure of a key protein that, when sensing certain viruses and bacteria, triggers the body's immediate immune response.

20 Jun 2012

High doses of tiny milk vitamin produces numerous health benefits in mice

A novel form of vitamin B3 found in milk in small quantities produces remarkable health benefits in mice when high doses are administered, according to a new study conducted by researchers at Weill Cornell Medical College and the Polytechnic School in Lausanne, Switzerland.

15 Jun 2012

European launch of technology for quantitative assessment of Parkinson’s disease symptoms from Great Lakes NeuroTechnologies

Great Lakes NeuroTechnologies announced today that they are launching the latest version of their medical device technology for assessing Parkinson’s disease next week at the Movement Disorders Society Congress in Dublin, Ireland.

14 Jun 2012

Targeting noradrenergic system combats gait freezing in Parkinson’s patients

Methylphenidate may be a useful treatment for patients with advanced Parkinson's disease receiving subthalamic nucleus stimulation who experience gait hypokinesia and freezing, show findings from a randomized trial.

14 Jun 2012

Mazor Robotics successfully completes first robot-guided brain surgical procedures

Mazor Robotics Ltd., a developer of innovative surgical robots and complementary products, today announced the successful completion of the first robot-guided brain surgical procedures, which were performed with Mazor Robotics' technology.

11 Jun 2012

Patent claims for technology to assess Parkinson’s disease issued to Great Lakes Neurotechnologies

Great Lakes NeuroTechnologies announced today that the U.S. Patent Office has issued claims under patent number 8,187,209 covering their Movement Disorder Monitoring System and Method for quantitative assessment of motor symptoms associated with movement disorders.

6 Jun 2012

NYU Langone establishes unique neuromodulation center

The Department of Neurosurgery at NYU Langone Medical Center has established a unique, multidisciplinary neuromodulation center for the treatment of complex neurological conditions including movement disorders like Parkinson's disease, chronic pain and psychiatric condition such as obsessive compulsive disorder and severe depression.

31 May 2012

Interim data from UCLA and NeuroSigma’s eTNS Phase I trial on PTSD, MDD

Today, at the 52nd annual New Clinical Drug Evaluation Unit (NCDEU) Conference in Arizona, Ian Cook, M.D., Professor of Psychiatry at the University of California, Los Angeles (UCLA) and a Senior Medical Advisor to NeuroSigma, Inc., presented the results from the first 6-subject cohort of a 10-subject Phase I open-label clinical trial studying the effects of external trigeminal nerve stimulation (eTNS) on Post-Traumatic Stress Disorder (PTSD) and depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy.

31 May 2012

Study shows how chromosomal mutation likely contributes to early development of prostate cancer

Up to half of all prostate cancer cells have a chromosomal rearrangement that results in a new "fusion" gene and formation of its unique protein -- but no one has known how that alteration promotes cancer growth. Now, Weill Cornell Medical College researchers have found that in these cancer cells, the 3-D architecture of DNA, wrapped up in a little ball known as a chromatin, is warped in such a way that a switch has been thrown on thousands of genes, turning them on or off to promote abnormal, unchecked growth. Researchers also found that new chromosomal translocations form, further destabilizing the genome.

23 May 2012

Medtronic fourth quarter revenue increases 4% to $4.297 billion

Medtronic, Inc. today announced financial results for its fourth quarter and fiscal year ended April 27, 2012.

From Medtronic 22 May 2012

Study uncovers distinct subtype of prostate cancer

A collaborative expedition into the deep genetics of prostate cancer has uncovered a distinct subtype of the disease, one that appears to account for up to 15 percent of all cases, say researchers at Weill Cornell Medical College, the Broad Institute of MIT and Harvard and the Dana-Farber Cancer Institute.

21 May 2012

Researchers identify novel base modification in RNA

Over the past decade, research in the field of epigenetics has revealed that chemically modified bases are abundant components of the human genome and has forced us to abandon the notion we've had since high school genetics that DNA consists of only four bases.

18 May 2012

Results reported for clinical trial for the treatment of depression using external trigeminal nerve stimulation

Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.

9 May 2012

eTNS therapy can impact symptoms in pharmacoresistant major depression

9 May 2012

DBS may offer hope for patients with mild Alzheimer's

A study on a handful of people with suspected mild Alzheimer's disease (AD) suggests that a device that sends continuous electrical impulses to specific "memory" regions of the brain appears to increase neuronal activity. Results of the study using deep brain stimulation, a therapy already used in some patients with Parkinson's disease and depression, may offer hope for at least some with AD, an intractable disease with no cure.

8 May 2012

Scientists identify first gene associated with congenital asplenia

Researchers at Weill Cornell Medical College and Rockefeller University have identified the first gene to be linked to a rare condition in which babies are born without a spleen, putting those children at risk of dying from infections they cannot defend themselves against. The gene, Nkx2.5, was shown to regulate genesis of the spleen during early development in mice.

4 May 2012

Conference to focus on deep brain stimulation for OCD, depression

Deep brain stimulation, increasingly recognized as an effective therapy for certain cases of Parkinson's disease, dystonia and tremor, also may help patients who suffer from obsessive-compulsive disorder or depression that fails to respond to other treatments.

27 Apr 2012

New article describes design and properties of magnetoelectric composite materials

Up to now, the brain's magnetic field is measurable only under technical laboratory conditions. This technique is therefore not feasible in terms of the broader medical use, although it would be significant for diagnosing numerous conditions such as epilepsy and dementia, or even for improving therapies such as deep brain stimulation for treating Parkinson's disease.

27 Apr 2012

Great Lakes NeuroTechnologies secures funding for development and testing of innovative neurotechnology

Great Lakes NeuroTechnologies Secures Over $4.5 Million in Funding to Fuel New Product Development for Parkinson's Disease and Neuroscience Education April 24, 2012: Valley View, OH - Great Lakes NeuroTechnologies announced today they have secured over $4.5 million is funding for new product development. The funding includes three new projects sponsored by the National Institutes of Health's SBIR program. Each project is focused on developing and testing innovative neurotechnology. Two projects focus on the monitoring and treatment of Parkinson's disease while another will develop a wireless physiological monitor and web-based teaching system for high school neuroscience courses.

26 Apr 2012

Deep Brain Stimulation News and Research

Further Reading

NewYork-Presbyterian/WCMC join new MDS Clinical Research Consortium

Researchers unlock structure of STING protein

High doses of tiny milk vitamin produces numerous health benefits in mice

European launch of technology for quantitative assessment of Parkinson’s disease symptoms from Great Lakes NeuroTechnologies

Targeting noradrenergic system combats gait freezing in Parkinson’s patients

Mazor Robotics successfully completes first robot-guided brain surgical procedures

Patent claims for technology to assess Parkinson’s disease issued to Great Lakes Neurotechnologies

NYU Langone establishes unique neuromodulation center

Interim data from UCLA and NeuroSigma’s eTNS Phase I trial on PTSD, MDD

Study shows how chromosomal mutation likely contributes to early development of prostate cancer

Medtronic fourth quarter revenue increases 4% to $4.297 billion

Study uncovers distinct subtype of prostate cancer

Researchers identify novel base modification in RNA

Results reported for clinical trial for the treatment of depression using external trigeminal nerve stimulation

eTNS therapy can impact symptoms in pharmacoresistant major depression

DBS may offer hope for patients with mild Alzheimer's

Scientists identify first gene associated with congenital asplenia

Conference to focus on deep brain stimulation for OCD, depression

New article describes design and properties of magnetoelectric composite materials

Great Lakes NeuroTechnologies secures funding for development and testing of innovative neurotechnology

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Latest News